ENLV
Price:
$0.6701
Market Cap:
$16.29M
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Industry
Biotechnology
IPO Date
2014-07-31
Stock Exchange
NASDAQ
Ticker
ENLV
According to Enlivex Therapeutics Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 0.03. This represents a change of -101.51% compared to the average of -1.99 of the last 4 quarters.
The mean historical PE Ratio of Enlivex Therapeutics Ltd. over the last ten years is -3.33. The current 0.03 PE Ratio has changed -190.03% with respect to the historical average. Over the past ten years (40 quarters), ENLV's PE Ratio was at its highest in in the December 2025 quarter at 0.01. The PE Ratio was at its lowest in in the September 2019 quarter at -28.51.
Average
-3.33
Median
-1.66
Minimum
-9.39
Maximum
0.03
Discovering the peaks and valleys of Enlivex Therapeutics Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.23%
Maximum Annual PE Ratio = 0.03
Minimum Annual Increase = -101.63%
Minimum Annual PE Ratio = -9.39
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 0.03 | -101.63% |
| 2024 | -1.60 | -7.34% |
| 2023 | -1.73 | -26.06% |
| 2022 | -2.33 | -69.76% |
| 2021 | -7.72 | -17.83% |
| 2020 | -9.39 | 21.41% |
| 2019 | -7.73 | 1.23% |
| 2018 | -0.58 | -52.94% |
| 2017 | -1.24 | 19.85% |
| 2016 | -1.03 | -71.19% |
The current PE Ratio of Enlivex Therapeutics Ltd. (ENLV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.10
5-year avg
-2.67
10-year avg
-3.33
Enlivex Therapeutics Ltd.’s PE Ratio is greater than CollPlant Biotechnologies Ltd. (-0.35), greater than Lisata Therapeutics, Inc. (-1.96), greater than NuCana plc (-0.17), greater than MetaVia Inc. (-0.64), greater than Exicure, Inc. (-1.81), greater than Cadrenal Therapeutics, Inc. Common Stock (-0.75), greater than NeuroSense Therapeutics Ltd. (-2.87), greater than NeurAxis, Inc. (-10.07), greater than CytoMed Therapeutics Limited (-3.17), greater than Passage Bio, Inc. (-0.49),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.35 | $4.14M | |
| -1.96 | $32.42M | |
| -0.17 | $11.84M | |
| -0.64 | $3.83M | |
| -1.81 | $17.72M | |
| -0.75 | $10.61M | |
| -2.87 | $18.13M | |
| -10.07 | $82.98M | |
| -3.17 | $13.49M | |
| -0.49 | $18.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enlivex Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Enlivex Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Enlivex Therapeutics Ltd.'s PE Ratio?
How is the PE Ratio calculated for Enlivex Therapeutics Ltd. (ENLV)?
What is the highest PE Ratio for Enlivex Therapeutics Ltd. (ENLV)?
What is the 3-year average PE Ratio for Enlivex Therapeutics Ltd. (ENLV)?
What is the 5-year average PE Ratio for Enlivex Therapeutics Ltd. (ENLV)?
How does the current PE Ratio for Enlivex Therapeutics Ltd. (ENLV) compare to its historical average?